Dronabinol in Severe, Enduring Anorexia Nervosa: A Randomized Controlled Trial
Dronabinol in Severe, Enduring Anorexia Nervosa: A Randomized Controlled Trial
复制标题
DOI：
10.1002/eat.22173
复制
发表时间：
2014-01-01
影响因子：
5.5
通讯作者：
Stoving, Rene Klinkby
中科院分区：
文献类型：
--
作者：
Andries, Alin;Frystyk, Jan;Stoving, Rene Klinkby
药物治疗严重、长期存在的神经性厌食症（AN）的证据很少，少数对照药理学研究集中在狭窄的药物范围内。本研究的目的是调查与合成大麻素激动剂的治疗对体重和进食障碍相关的精神病理人格特征的妇女严重，持久的AN.MethodThis添加，前瞻性，随机，双盲，对照交叉研究的影响进行了2008年和2011年之间在一个专门的护理中心进食障碍。25名年龄超过18岁且AN持续时间至少5年的女性被随机分配至屈大麻酚-安慰剂或安慰剂-屈大麻酚治疗组。除了标准化的基线治疗方案外，参与者还接受了屈大麻酚，2.5 mg，每日两次，持续4周，并匹配安慰剂4周，中间间隔4周的洗脱期。主要结局是体重的平均变化。次要结局是进食障碍量表-2（EDI-2）的评分变化。结果在屈大麻酚治疗期间，参与者增加了0.73 kg（t=2.86，df=22，p
ObjectiveThe evidence for pharmacological treatment of severe, longstanding anorexia nervosa (AN) is sparse and the few controlled pharmacologic studies have focused on a narrow range of drugs. The aim of the present study was to investigate the effects of treatment with a synthetic cannabinoid agonist on body weight and eating disorder-related psychopathological personality traits in women with severe, enduring AN.MethodThis add-on, prospective, randomized, double blind, controlled crossover study was conducted between 2008 and 2011 at a specialized care center for eating disorders. Twenty-five women over 18 years with AN of at least 5 years duration were randomized to treatment with either dronabinol-placebo or placebo-dronabinol. In addition to the standardized baseline therapeutic regime, the participants received dronabinol, 2.5 mg twice daily for 4 weeks and matching placebo for 4 weeks, separated by a 4-week wash-out period. Primary outcome was the mean change in body weight. Secondary outcome was score changes on the Eating Disorder Inventory-2 (EDI-2). Data were analyzed for the 24 patients who completed the trial.ResultsDuring dronabinol treatment, participants gained 0.73 kg (t=2.86, df=22, p